Management of Hypertension in Patients with Ischemic Heart Disease

Current Cardiology Reports

Volumn 17, Issue 12, 2015, Pages

  Agbor Etang, Brian B ^a   Setaro, John F ^b  

^a GREENWICH HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hypertension; Ischemic heart disease

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL PLUS VERAPAMIL; VERAPAMIL;

ANGINA PECTORIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; COMORBIDITY; DRUG CONTRAINDICATION; DRUG EFFICACY; HEART INFARCTION; HEART WORK; HUMAN; HYPERTENSION; HYPOKALEMIA; ISCHEMIC HEART DISEASE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIMARY PREVENTION; REVIEW; BLOOD PRESSURE MEASUREMENT; COMPLICATION; MYOCARDIAL ISCHEMIA; PROGNOSIS; RISK FACTOR; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; CALCIUM CHANNEL BLOCKERS; HUMANS; HYPERTENSION; MYOCARDIAL ISCHEMIA; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK FACTORS; UNITED STATES;

EID: 84945183714     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-015-0662-0     Document Type: Review

References (34)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.
2. Mozaffarian D, Benjamin EJ, Go AS, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322. Key source on current cardiovascular epidemiology.
3. Gillespie CD, Wigington C, Hong Y. National center for chronic disease prevention and health promotion, CDC. Coronary heart disease and stroke deaths—United States, 2009. Morbidity and mortality weekly report: Supplement-CDC Health Disparities and Inequalities Report—United States. 2013 Nov. 62(03):157–160.
4. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U.S. deaths from coronary disease 1980–2000. N Engl J Med. 2007;356:2388–98.
5. Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011–2012. NCHS Data Brief. 2013. Best contemporary source on hypertension prevalence in US population.
6. James PA, Oparil S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20. Source document for the present controversy regarding BP goals in older individuals.
7. Navar-Boggan AM, Pencina MJ, Williams K, Sniderman AD, Peterson ED. Proportion of US adults potentially affected by the 2014 hypertension guideline. JAMA. 2014;311:1424–9.
8. Lloyd-Jones DM. Chapter B77. Ischemic heart disease risk. In: Izzo Jr JL, Sica DA, Black HR, editors. Hypertension primer: the essentials of high blood pressure: basic science, population science and clinical management. 4e. Philadelphia: Williams and Wilkins; 2008. p. 249–53.
9. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.
10. Roberts R, Stewart AF. The genetics of coronary artery disease. 2012;27(3):221–7.
11. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111(25):3481–8.
12. Crawford MH. Chapter 6. Chronic ischemic heart disease. In: Crawford MH, editor. Current diagnosis & treatment: cardiology, 4e. New York: McGraw-Hill; 2014.
13. Mohrman DE, Heller L. Chapter 1. Overview of the cardiovascular system. In: Mohrman DE, Heller L, editors. Cardiovascular physiology, 8e. New York: McGraw-Hill; 2014.
14. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J. 2010;31:2897–908.
15. Moser M. Drug treatment of hypertension: general information, the so-called J-Shaped curve. In: Moser M, editor. Clinical management of hypertension. 9e. West Islip: Professional Communications, Inc; 2013. p. 64–5. Well-reasoned critique of the J-curve hypothesis.
16. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Coll Cardiol. 2015;65:1998–2038. State-of-the-Art literature review and persuasive guideline recommendations for treating BP patients who have IHD.
17. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J. Factors of risk in the development of coronary heart disease—six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33–50.
18. Rosendorff C. Chapter C149. Treatment of hypertensive patients with ischemic heart disease. In: Izzo Jr JL, Sica DA, Black HR, editors. Hypertension primer: the essentials of high blood pressure: basic science, population science and clinical management. 4e. Philadelphia: Williams and Wilkins; 2008. p. 496–501.
19. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–16.
20. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.
21. Fox KM. European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA Study). Lancet. 2003;362:782–8.
22. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–31.
23. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. American College of Cardiology Foundation. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:3097–137.
24. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.
25. Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2011;124:2458–73.
26. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–28.
27. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.
28. Kaplan NM, Victor RG. Treatment of hypertension: drug therapy. In: Kaplan NM, Victor RG. editors. Kaplan’s clinical hypertension, 11e. Lippincott Williams and Wilkins; 2015. p. 240.
29. Elliot WJ. Management of high blood pressure. In: Wong ND, Amsterdam EA, Blumenthal RS, editors. American society of preventive cardiology. Manual of preventive cardiology. New York: Demos Medical Publishing; 2015. p. 40–1.
30. Wright Jr JT, Fine LJ, Lackland DT, Ogedegbe G, Himmelfarb CRD. Evidence supporting a systolic blood pressure goal of less than 150 mmHg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014;160(7):499–503. The minority report of the JNC-8 panel, furnishing sound arguments for retaining the 140/90 mmHg BP target.
31. Krakoff LR, Gillespie RL, Ferdinand KC, Fergus IV, Akinboboye O, Williams KA, et al. Hypertension recommendations from the Eighth Joint National Committee panel members raise concerns for elderly black and female populations. J Am Coll Cardiol. 2014;64:394–402. Incisive analysis of how relaxing BP target will injure vulnerable populations.
32. Borden WB, Maddox TM, Tang F, Rumsfeld JS, Oetgen WJ, Mullen JB, et al. Impact of the 2014 Expert Panel recommendations for management of high blood pressure on contemporary cardiovascular practice: insights from the NCDR PINNACLE Registry. J Am Coll Cardiol. 2014;64:2196–203. Revealing examination of the potential impact on cardiac patients if BP goals are set at 150/90 mmHg.
33. Rosendorff C. Blood pressure targets. Still struggling for the right answer. J Am Coll Cardiol. 2014;64:2204–6.
34. Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, Cutler JA, et al. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.